Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AVTX
SellHot AirAvalo Therapeutics, Inc. · Healthcare · United States · $1.1B · Avg Vol: $14M/d
COMPANY DESCRIPTION
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases and cancers. The company leverages a pipeline of innovative drug candidates, often in-licensed, to address significant unmet medical needs in specialized patient populations. Its strategy involves targeted development and potential partnerships to bring novel treatments to market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.1M | 1.9M | 0.4M | 59.0K | -85.2% | 59.0K | — | — | — |
| EPS | -0.79 | -1.73 | -1.58 | -2.06 | — | -4.41 | -2.72 | -2.74 | — |
| Shares | 52.6M | 52.6M | 52.6M | 52.6M | 0.0% | 53.6M | — | — | — |
| Debt | 19.9M | 0.5M | 0.6M | 0.4M | -73.0% | 0.2M | — | — | — |
| Equity | -10.9M | 7.3M | 133.0M | 83.0M | 237.2% | — | — | — | — |
| Op CF | -26.8M | -30.7M | -49.1M | -51.5M | — | -68.3M | — | — | — |
| Inv CF | -95.0K | -0.1M | 0.4M | -81.7M | — | — | — | — | — |
| Fin CF | -14.7M | 25.0M | 175.8M | 14.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc.(you) | $1.1B | 26 | Sell |
| IMMX | Immix Biopharma, Inc. | $992M | 26 | Sell |
| CADL | Candel Therapeutics, Inc. | $1.0B | 27 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 28 | Sell |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 28 | Sell |
| KURA | Kura Oncology, Inc. | $1.1B | 23 | Sell |
| MNKD | MannKind Corporation | $1.3B | 25 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
| ACRS | Aclaris Therapeutics, Inc. | $885M | 24 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 29 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%